Table 3.
No. (%) | |
---|---|
Operation (breast) | |
Modified radical mastectomy | 165 (72.1) |
Total mastectomy | 43 (18.9) |
Breast conserving surgery | 11 (4.8) |
Node excision | 2 (0.9) |
Not done | 6 (2.6) |
Not assessed | 1 (0.4) |
Operation (axilla) | |
ALND | 135 (61.1) |
SLNB | 53 (24.0) |
Not done | 16 (7.2) |
Not assessed | 17 (7.7) |
Neoadjuvant chemotherapy | |
No | 212 (95.9) |
Yes | 9 (4.1) |
AC followed by taxane | 5 (2.3) |
DA | 2 (0.9) |
Others | 2 (0.9) |
Adjuvant chemotherapy | |
Yes | 108 (48.6) |
AC followed by taxane | 32 (14.5) |
AC or EC | 30 (13.6) |
CMF | 14 (6.3) |
FAC or FEC | 13 (5.9) |
TAC | 4 (1.8) |
AC followed by taxane with trastuzumab | 3 (1.4) |
TC | 2 (0.9) |
AC followed by trastuzumab | 1 (0.5) |
Others | 7 (3.2) |
Not assessed | 2 (0.9) |
Completion of chemotherapy | |
Yes | 86 (38.9) |
No | 15 (6.8) |
Not assessed | 6 (2.7) |
No | 107 (48.2) |
Not assessed | 6 (3.2) |
Adjuvant endocrine treatment | |
Yes | 166 (83.0) |
Tamoxifen | 150 (75.0) |
Toremifen | 9 (4.5) |
Aromatase inhibitor | 2 (1.0) |
Others | 5 (2.5) |
Total duration of treatment, median (range, mo) | 48.5 (1.0–87) |
Completion of treatment | |
Yes | 68 (34.0) |
No | 63 (31.5) |
Ongoing | 23 (11.5) |
Not assessed | 12 (6.0) |
No | 25 (12.5) |
Not assessed | 9 (4.5) |
Adjuvant radiation treatment | |
No | 157 (71.9) |
Yes | 52 (24.0) |
Not assessed | 9 (4.1) |
AC, adriamycin-cyclophosphamide; ALND, axillary lymph node dissection; CMF, cyclophosphamide-methotrexate-5-fluorouracil; DA, docetaxel-adriamycin; EC, epirubicin-cyclophosphamide; FAC, 5-fluorouracil-adriamycin-cyclophosphamide; FEC, 5-fluorouracil-epirubicin-cyclophosphamide; SLNB, sentinel lymph node biopsy; TAC, docetaxel-adriamycin-cyclophosphamide; TC, docetaxel-cyclophosphamide.